LA JOLLA, Calif., Nov. 19, 2012 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the quarter ended September 30, 2012 and provided a summary of recent corporate highlights.
"The third quarter and subsequent period were the most successful to date for Regulus as measured by the achievement of significant financial and strategic goals," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "Regulus is now focused on the execution of our research and development plans that include selection of clinical candidates in all of our microRNA therapeutic programs, which we believe will enable us to file at least two INDs by 2014."
"The third quarter and subsequent period were the most successful to date for Regulus as measured by the achievement of significant financial and strategic goals," said Kleanthis G. Xanthopoulos, Ph.D., President and CEO of Regulus. "Regulus is now focused on the execution of our research and development plans that include selection of clinical candidates in all of our microRNA therapeutic programs, which we believe will enable us to file at least two INDs by 2014."
